Total Payments
$893,748
2024 Payments
$130,119
Companies
50
Transactions
1,321
Medicare Patients
746
Medicare Billing
$153,188
Payment Breakdown by Category
Other$553,276 (61.9%)
Consulting$172,164 (19.3%)
Travel$90,400 (10.1%)
Research$50,848 (5.7%)
Food & Beverage$26,915 (3.0%)
Education$145.30 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $542,476 | 187 | 60.7% |
| Consulting Fee | $172,164 | 69 | 19.3% |
| Travel and Lodging | $90,400 | 180 | 10.1% |
| Unspecified | $50,848 | 25 | 5.7% |
| Food and Beverage | $26,915 | 842 | 3.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,800 | 2 | 0.9% |
| Honoraria | $3,000 | 2 | 0.3% |
| Education | $145.30 | 14 | 0.0% |
Payments by Type
General
$842,900
1,296 transactions
Research
$50,848
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $205,762 | 371 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $115,921 | 77 | $0 (2022) |
| Janssen Biotech, Inc. | $114,242 | 133 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $103,052 | 82 | $0 (2024) |
| PFIZER INC. | $100,968 | 128 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $72,734 | 47 | $0 (2024) |
| UCB, Inc. | $58,801 | 77 | $0 (2020) |
| Daiichi Sankyo Inc. | $29,198 | 27 | $0 (2022) |
| Eli Lilly and Company | $27,063 | 42 | $0 (2023) |
| Takeda Pharmaceuticals America, Inc. | $18,894 | 18 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $130,119 | 199 | ABBVIE INC. ($60,829) |
| 2023 | $95,346 | 141 | AbbVie Inc. ($44,507) |
| 2022 | $105,660 | 170 | E.R. Squibb & Sons, L.L.C. ($38,605) |
| 2021 | $51,439 | 160 | E.R. Squibb & Sons, L.L.C. ($18,752) |
| 2020 | $59,089 | 80 | Takeda Pharmaceuticals U.S.A., Inc. ($11,509) |
| 2019 | $172,434 | 177 | PFIZER INC. ($68,441) |
| 2018 | $124,132 | 174 | Janssen Scientific Affairs, LLC ($37,358) |
| 2017 | $155,528 | 220 | UCB, Inc. ($43,549) |
All Payment Transactions
1,321 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $481.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $359.05 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $31.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/02/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Rare Disease | ||||||
| 11/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,729.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $481.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $75.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Immunology | ||||||
| 11/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 11/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $1,052.47 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk | Takeda Pharmaceuticals U.S.A., Inc. | $28,973 | 1 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,910 | 8 |
| Effects of Transient and Persistent Anti-Drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7 Year Study in Crohn's Disease | UCB, Inc. | $2,300 | 1 |
| Therapeutic Drug Monitoring Tumor Necrosis Factor Antagonists in Crohns Disease A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice | UCB, Inc. | $2,300 | 1 |
| Therapeutic Drug Monitoring Tumor Necrosis Factor Antagonists in Crohns Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice | UCB, Inc. | $2,300 | 1 |
| PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) | Celgene Corporation | $1,144 | 1 |
| RPC01-202 - PhII UC Touchstone (RPC01-202) (BMS Study Number: IM047-P21) | Celgene Corporation | $1,082 | 1 |
| PhII Stepstone RPC1063 Induction in Moderately to Severely CD as Induction with LT(RPC01-2201) (BMS Study Number: IM047-P13) (RPC01-2201) | Celgene Corporation | $886.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $655.13 | 1 |
| RPC01-3201 - PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) | Celgene Corporation | $442.00 | 1 |
| Healthcare costs of patients with Crohn's disease receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patients claims data | UCB, Inc. | $420.00 | 1 |
| RPC01-202 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 218 | 1,573 | $256,985 | $60,307 |
| 2022 | 6 | 168 | 1,154 | $182,772 | $46,455 |
| 2021 | 4 | 162 | 204 | $106,591 | $23,541 |
| 2020 | 7 | 198 | 329 | $104,114 | $22,885 |
Total Patients
746
Total Services
3,260
Medicare Billing
$153,188
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 13 | 1,320 | $125,400 | $34,583 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 75 | $41,025 | $10,238 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 76 | $29,792 | $6,271 | 21.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 35 | 36 | $28,548 | $4,908 | 17.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 34 | 36 | $21,600 | $2,204 | 10.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 11 | 12 | $6,480 | $1,242 | 19.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 18 | $4,140 | $861.39 | 20.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 12 | 970 | $92,150 | $28,012 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 56 | 67 | $26,264 | $5,984 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 41 | $22,427 | $5,335 | 23.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 26 | 27 | $21,411 | $4,150 | 19.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 25 | 25 | $15,000 | $1,782 | 11.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 17 | 24 | $5,520 | $1,192 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 55 | 82 | $41,229 | $11,203 | 27.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 47 | 61 | $22,586 | $5,816 | 25.7% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 31 | 32 | $25,376 | $4,703 | 18.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 29 | 29 | $17,400 | $1,820 | 10.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 46 | 65 | $27,430 | $6,234 | 22.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 77 | $24,178 | $6,024 | 24.9% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 20 | 21 | $16,653 | $3,217 | 19.3% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2020 | 17 | 104 | $7,800 | $2,618 | 33.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 14 | 17 | $9,180 | $1,928 | 21.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 23 | 24 | $14,400 | $1,775 | 12.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 21 | $4,473 | $1,088 | 24.3% |
About Dr. Douglas Wolf, MD
Dr. Douglas Wolf, MD is a Gastroenterology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1588649693.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Wolf, MD has received a total of $893,748 in payments from pharmaceutical and medical device companies, with $130,119 received in 2024. These payments were reported across 1,321 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($542,476).
As a Medicare-enrolled provider, Wolf has provided services to 746 Medicare beneficiaries, totaling 3,260 services with total Medicare billing of $153,188. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Atlanta, GA
- Active Since 12/12/2005
- Last Updated 02/05/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1588649693
Products in Payments
- STELARA (Biological) $176,342
- XELJANZ (Drug) $88,790
- SKYRIZI (Biological) $84,617
- Entyvio (Biological) $77,890
- ZEPOSIA (Drug) $60,083
- Cimzia (Drug) $55,801
- Humira (Biological) $43,002
- TREMFYA (Drug) $41,233
- ENTYVIO (Biological) $36,429
- RINVOQ (Biological) $31,161
- INJECTAFER (Drug) $29,182
- HUMIRA (Biological) $10,077
- UCERIS (Drug) $8,800
- SIMPONI (Biological) $8,089
- VELSIPITY (Drug) $5,534
- REMICADE (Biological) $5,338
- Mytesi (Drug) $3,137
- RPC-1063 (Drug) $2,030
- Ozanimod (Drug) $1,959
- Tremfya (Drug) $1,487
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Atlanta
Enrique Martinez, Md, MD
Gastroenterology — Payments: $691,094
Gastroenterology $691,094
Dr. Kavita Kongara, M.d, M.D
Gastroenterology — Payments: $576,854
Gastroenterology $576,854
Girish Anand, M.d, M.D
Gastroenterology — Payments: $482,731
Gastroenterology $482,731
Dr. Norman Gitlin, Md, MD
Gastroenterology — Payments: $440,956
Gastroenterology $440,956
Dr. Hetal Karsan, Md, MD
Gastroenterology — Payments: $371,430
Gastroenterology $371,430
Dr. Marc Sonenshine, Md, MD
Gastroenterology — Payments: $311,059
Gastroenterology $311,059